63
Participants
Start Date
November 21, 2022
Primary Completion Date
July 17, 2025
Study Completion Date
February 27, 2029
Garetosmab
Garetosmab is supplied as a liquid drug product and will be administered IV.
Placebo
Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.
Royal North Shore Hospital, St Leonards
University of Cape Town, Rondebosch
IRCCS Istituto Giannina Gaslini, Genoa
Hospital Universitario Ramon y Cajal, Madrid
Hôpital Lapeyronie, Montpellier
Vanderbilt University Medical Center, Nashville
Hospital Kuala Lampur, Kuala Lumpur
Hopital Lariboisiere, Paris
University of California Los Angeles (UCLA) Medical Center, Los Angeles
Clinica Universidad de La Sabana, Chía
Tongji Hospital of Tongji University, Shanghai
Universidad de Concepcion, Concepción
Queen Mary Hospital, Hong Kong
Hospital Israelita Albert Einstein, São Paulo
HUS Children and Adolescents Park Hospital Clinical Trial Unit, Helsinki
Nagoya University Hospital, Nagoya
Oita University Hospital, Yufu
Kyushu University Hospital, Fukuoka
Amsterdam University Medical Center, Amsterdam
Szpital Centrum Medyczne Medyk, Rzeszów
Seoul National University Hospital, Seoul
Royal National Orthropaedic Hospital NHS Trust, Middlesex
Regeneron Pharmaceuticals
INDUSTRY